Gitlab Inc. GTLB
Gitlab Inc. (GTLB) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $955.2M at a -5.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.08 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-12 | Macquarie | Neutral (main) |
| 2026-06-11 | BTIG | Buy (reit) |
| 2026-06-03 | Macquarie | Neutral (main) |
| 2026-06-03 | UBS | Neutral (main) |
| 2026-06-03 | Mizuho | Neutral (main) |
| 2026-06-03 | Morgan Stanley | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.583 |
| Retained earnings / assets | -0.71 |
| EBIT / assets | -0.041 |
| Equity / liabilities | 1.509 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GTLB | Gitlab Inc. | 4/9 | 2.82 | — | +25.8% |
| APPF | APPFOLIO INC | 5/9 | 9.77 | 39.1 | +19.7% |
| TTAN | ServiceTitan, Inc. | 6/9 | 5.85 | — | +24.5% |
| GLBE | Global-E Online Ltd. | 6/9 | 3.12 | 90.4 | +27.8% |
| PRGS | PROGRESS SOFTWARE CORP /MA | 7/9 | -0.25 | 19.1 | +29.8% |
| TENB | Tenable Holdings, Inc. | 5/9 | -1.62 | — | +11% |
| YOU | Clear Secure, Inc. | 4/9 | 1.48 | 64.6 | +16.9% |
About Gitlab Inc.
GitLab Inc., together with its subsidiaries, develops software for the software development lifecycle in the United States, Europe, and the Asia Pacific. The company provides GitLab, an intelligent orchestration platform for DevSecOps, which is a single application offering the entire software development lifecycle, including software, project plans, code, security scans, compliance checks, and deployment configurations. It also offers the GitLab Duo Agent Platform, which enables intelligent orchestration of teams and AI agents to execute tasks autonomously across planning, development, security, and deployment. This platform combines conversational AI assistance, purpose-built agents for specialized tasks, workflow automation, and enterprise controls. In addition, it offers related training and professional services. The company was formerly known as GitLab B.V. and changed its name to GitLab Inc. in July 2015. GitLab Inc. was founded in 2011 and is based in San Francisco, California.
FAQ
Is GTLB financially healthy?
Gitlab Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does GTLB pay a dividend?
No, Gitlab Inc. does not currently pay a dividend.
How profitable is GTLB?
In FY2026, Gitlab Inc. had a net margin of -5.9% and a return on equity of -5.4%.
What is the analyst price target for GTLB?
The average Wall-Street price target for Gitlab Inc. is $33.61, about 17.6% below the recent price, from 23 analysts (consensus: hold).
Is GTLB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Gitlab Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-31. Facts plus Stocktoria's own computed scores — not investment advice.